Heart Failure with Reduced Ejection Fraction
On this page
Direct answer
Heart failure with reduced ejection fraction (HFrEF) is defined by an LVEF of 40 per cent or less with symptoms. Management rests on four pillars initiated early and titrated upward regardless of aetiology: an ARNI (or ACE inhibitor/ARB), an evidence-based beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor — each reduces mortality. Devices are reassessed after at least three months of optimised drug therapy; advanced therapies (transplant, ventricular assist devices) are reserved for refractory patients. Loop diuretics decongest symptoms but do not alter survival.
What you must remember
- The four pillars: sacubitril-valsartan (superior to an ACE inhibitor in PARADIGM-HF), an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol or nebivolol), spironolactone or eplerenone, and dapagliflozin or empagliflozin regardless of diabetes.
- Start low, titrate fast: initiate all four classes early and titrate to target or maximally tolerated doses; sequencing is flexible, and hypotension is managed by spacing doses rather than abandoning classes.
- Ejection fraction categories: HFrEF 40 per cent or less; mildly reduced 41–49 per cent (SGLT2 inhibitors, cautious GDMT); preserved 50 per cent or more, where SGLT2 inhibitors have the strongest evidence.
- Add-on drugs: ivabradine for sinus rhythm with a resting rate of 70 or more despite maximally tolerated beta-blockade; digoxin for symptom and hospitalisation reduction without survival benefit; vericiguat after recent worsening; hydralazine–isosorbide dinitrate for ACE/ARNI intolerance or add-on use.
- Device timing: ICD for primary prevention with EF 35 per cent or less in NYHA class II–III after at least three months of optimised GDMT (and 40 days post-infarction in ischaemic disease); CRT with EF 35 per cent or less, sinus rhythm, LBBB and QRS of 150 ms or more.
- Decongestion: intravenous loop diuretics for congestion with potassium and renal monitoring; potassium binders help retain mineralocorticoid antagonist therapy.
- Advanced heart failure flags: recurrent admissions, GDMT intolerance from hypotension or renal dysfunction, progressive cachexia and refractory congestion — refer for transplant or assist-device assessment.
Common confusion
Candidates mix mortality-reducing drugs with symptom-only drugs: the four pillars versus digoxin and diuretics, which do not improve survival. The second confusion is device timing — the EF must be reassessed after three months of GDMT, and the 40-day post-MI rule applies only to ischaemic primary prevention. Third, a low blood pressure during initiation usually indicates slower titration, not withdrawal; congestion, not EF alone, drives diuretic intensity.
Exam-focused takeaway
NEET-SS and INI-SS stems on HFrEF are pharmacology-sequencing questions: which drug to add next, which to withhold in hyperkalaemia or bradycardia, and which four to start in a new diagnosis. Expect trial-name anchoring (PARADIGM-HF, DAPA-HF, SHIFT) and device-threshold questions quoting an EF of 36 per cent or a QRS of 140 ms to test the CRT LBBB boundary of 150 ms. Learn each pillar with its headline trial and one key adverse effect.
Frequently asked questions
What are the four pillars of HFrEF therapy?
An ARNI (or ACE inhibitor/ARB), an evidence-based beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor — all four started early and titrated, each with mortality benefit.
Which beta-blockers are evidence-based in HFrEF?
Carvedilol, metoprolol succinate, bisoprolol and nebivolol only; other beta-blockers lack outcome evidence and are distractors.
When is ivabradine indicated?
Sinus rhythm with a resting heart rate of 70 beats per minute or more despite maximally tolerated beta-blockade, in patients with EF 35 per cent or less; it reduces hospitalisation, not mortality.
When is an ICD implanted for primary prevention?
EF 35 per cent or less in NYHA class II–III on at least three months of optimised GDMT, at least 40 days after myocardial infarction in ischaemic cardiomyopathy, with expected survival beyond one year.